Further, objective responses and prolonged PFS were observed in a number of patients.

Osimertinib plus bevacizumab combination therapy is expected to prolong PFS and reduce adverse events.

PD-L1 expression in tumor samples was associated with prolonged PFS, but not with overall survival.

Discussion: These data indicate that the high response rate of MLS to trabectedin translates into prolonged PFS.

Furthermore, patients with lower absolute early and late residual TLG and TLP levels had a significantly prolonged PFS.